person · Reporting owner

Ratcliffe Liam

Disclosed activity across 12 companies

Tapewire entity: 24504
SEC CIK: 0001547100

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARVINAS, INC.ARVN · Entity 5355	Director	June 16, 2022	June 22, 2022
Aptinyx Inc.APTX · Entity 120922	Director	March 29, 2019	April 02, 2019
Climb Bio, Inc.ELYM · Entity 5064	Director	June 26, 2024	June 28, 2024
Cogent Biosciences, Inc.UMRX · Entity 3793	Director	June 14, 2019	June 18, 2019
Deciphera Pharmaceuticals, Inc.DCPH · Entity 90033	Director · 10% owner	May 17, 2018	May 21, 2018
Disc Medicine, Inc.IRON · Entity 2273	Director	June 18, 2026	June 23, 2026
Iterum Therapeutics plcITRM · Entity 72802	10% owner	May 30, 2018	May 31, 2018
OnKure Therapeutics, Inc.OKUR · Entity 6550	Director	August 07, 2026	August 11, 2026
Passage BIO, Inc.PASG · Entity 7829	Director	May 27, 2021	May 28, 2021
Upstream Bio, Inc.UPB · Entity 5743	Director	June 09, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARVINAS, INC.

Report date June 16, 2022 · Filed June 22, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.79 · Expires 2032-06-15	Direct	10,192	Reported balance After 2022-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-16 · Grant · Acquired 10,192 · Balance 10,192 F1: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.

Aptinyx Inc.

Report date March 29, 2019 · Filed April 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2029-03-28	Direct	4,123	Reported balance After 2019-03-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-03-29 · Grant · Acquired 4,123 · Balance 4,123 F1: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2: This option is fully vested at time of grant.

Climb Bio, Inc.

Report date June 26, 2024 · Filed June 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2034-06-25	Direct	10,000	Reported balance After 2024-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-26 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Cogent Biosciences, Inc.

Report date June 14, 2019 · Filed June 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2029-06-14	Direct	7,881	Reported balance After 2019-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-14 · Grant · Acquired 7,881 · Balance 7,881 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2: This option is fully vested at time of grant.

Deciphera Pharmaceuticals, Inc.

Report date May 17, 2018 · Filed May 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.73 · Expires 2028-05-16	Direct	12,000	Reported balance After 2018-05-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-17 · Grant · Acquired 12,000 · Balance 12,000 F1: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer.

Disc Medicine, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17	Direct	6,212	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Iterum Therapeutics plc

Report date May 30, 2018 · Filed May 31, 2018

Jointly reported with Lathi Vijay K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy New Leaf Ventures III, L.P.	1,071,688	Last balance in matching sequence After 2018-05-30 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2018-05-30 · Conversion · Acquired 466,793 · Balance 466,793 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 2 · 2018-05-30 · Conversion · Acquired 178,230 · Balance 645,023 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 3 · 2018-05-30 · Conversion · Acquired 148,603 · Balance 793,626 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 4 · 2018-05-30 · Purchase · Acquired 278,062 · Balance 1,071,688 F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Ordinary SharesSEC Table I · non-derivative	IndirectBy New Leaf Biopharma Opportunities II, L.P.	384,615	Reported balance After 2018-05-30 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2018-05-30 · Purchase · Acquired 384,615 · Balance 384,615 F5: These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors are the managing directors of NBPO-IIM and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors, NBPO-IIA and NBPO-IIM each disclaim Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of their respective pecuniary interest therein, if any.
Series A Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-30 · Conversion · Disposed 466,793 · Balance 0 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Series B-1 Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-30 · Conversion · Disposed 178,230 · Balance 0 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Series B-2 Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-05-30 · Conversion · Disposed 148,603 · Balance 0 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.

F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F5: These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors are the managing directors of NBPO-IIM and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors, NBPO-IIA and NBPO-IIM each disclaim Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of their respective pecuniary interest therein, if any.

F6: Not applicable.

OnKure Therapeutics, Inc.

Report date August 07, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06	Direct	22,350	Reported balance After 2026-08-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Passage BIO, Inc.

Report date May 27, 2021 · Filed May 28, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2031-05-26	Direct	16,918	Reported balance After 2021-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-27 · Grant · Acquired 16,918 · Balance 16,918 F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Upstream Bio, Inc.

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2036-06-08	Direct	17,096	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 17,096 · Balance 17,096 F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2019-03-15 transaction · row 1 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F5: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F6: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,172,434	Reported balance Holding disclosure · report date 2019-03-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,172,434 F2: New Leaf Growth Fund I, L.P. ("NLG I") is the direct beneficial owner of the securities reported. New Leaf Growth Associates I, L.P. ("NLG Growth Associates") is the sole general partner of NLG I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLG Growth Associates. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLG I. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLG I in which such Reporting Person has no pecuniary interest. Cancel
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,172,434	Reported balance Holding disclosure · report date 2019-03-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,172,434 F3: New Leaf Ventures III, L.P. ("NLV III") is the direct beneficial owner of the securities reported. New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLV III. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLV III in which such Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: New Leaf Growth Fund I, L.P. ("NLG I") is the direct beneficial owner of the securities reported. New Leaf Growth Associates I, L.P. ("NLG Growth Associates") is the sole general partner of NLG I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLG Growth Associates. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLG I. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLG I in which such Reporting Person has no pecuniary interest. Cancel

F3: New Leaf Ventures III, L.P. ("NLV III") is the direct beneficial owner of the securities reported. New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLV III. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLV III in which such Reporting Person has no pecuniary interest.

F4: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F5: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F6: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

iRhythm Holdings, Inc.

Report date October 25, 2016 · Filed October 25, 2016

Jointly reported with New Leaf Ventures II, L.P., Delagardelle Jeani, HUNT RONALD, New Leaf Venture Associates II, L.P., New Leaf Venture Management II, L.L.C., Chambon Philippe O.

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,741,589	Last balance in matching sequence After 2016-10-25 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2016-10-25 · Conversion · Acquired 1,716,589 · Balance 1,716,589 F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date. F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest. Row 2 · 2016-10-25 · Purchase · Acquired 25,000 · Balance 1,741,589 F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Conversion · Disposed 610,136 · Balance 0 F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Conversion · Disposed 190,154 · Balance 0 F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series E Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-25 · Conversion · Disposed 155,548 · Balance 0 F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series D Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-11-01	Direct	0	Reported balance After 2016-10-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-10-25 · Conversion · Disposed 72,389 · Balance 0 F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date.

F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016.

F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	484	$89.65	$43,390.60	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 8 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	795	$90.29	$71,780.55	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 7 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.11 to $90.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	5,221	$91.59	$478,191.39	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 6 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $92.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	4,940	$90.75	$448,305.00	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 5 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.75 to $90.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	7,060	$91.50	$645,990.00	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,440 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.15 to $92.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	6,423	$91.50	$587,704.50	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $91.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionCommon Stock	12,000	$33.57	$402,840.00	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionCommon Stock	6,423	$22.06	$141,691.38	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 09, 2021 Filed Aug 11, 2021 21:23 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $12.50	$0.00	Disclosure SEC source: 0001209191-21-050959 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-08 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021. Read SEC document
June 08, 2021 Filed Jun 11, 2021 00:00 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	7,511	$0.00 Strike: $78.53	$0.00	Disclosure SEC source: 0001209191-21-039678 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 7,511 shares Expires 2021-06-07 F1 · derivative.exercise_date: This option award was granted on June 8, 2021. The shares underlying the award shall vest in full on June 8, 2022 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
May 27, 2021 Filed May 28, 2021 21:58 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (Right to Buy) · Derivative	16,918	$0.00 Strike: $13.83	$0.00	Disclosure SEC source: 0001209191-21-036622 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
December 18, 2020 Filed Dec 21, 2020 23:00 UTC	ARVINAS, INC. ARVN · Entity 5355	PurchaseCommon Stock	142,857	$70.00	$9,999,990.00	Disclosure SEC source: 0001209191-20-064697 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 822,857 F1 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
June 03, 2020 Filed Jun 5, 2020 01:00 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $33.57	$0.00	Disclosure SEC source: 0001209191-20-034584 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-02 F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
May 26, 2020 Filed May 27, 2020 22:34 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionStock Option (right to buy) · Derivative	6,500	$0.00 Strike: $22.06	$0.00	Disclosure SEC source: 0001209191-20-032410 · doc4.xml · derivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,423 Underlying: Common Stock · 6,500 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020. Read SEC document
May 26, 2020 Filed May 27, 2020 22:34 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionCommon Stock	6,500	$22.06	$143,390.00	Disclosure SEC source: 0001209191-20-032410 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2020 Filed Mar 3, 2020 23:48 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	2,800	$18.00	$50,400.00	Disclosure SEC source: 0001209191-20-015640 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Read SEC document
March 03, 2020 Filed Mar 13, 2020 21:20 UTC Amendment	Passage BIO, Inc. PASG · Entity 7829	ConversionSeries B Preferred Stock · Derivative	2,066,630	$0.00	$0.00	Disclosure SEC source: 0001209191-20-018974 · doc4a.xml · derivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By AI Passage LLC Disclosed balance after: 0 Underlying: Common Stock · 2,066,630 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F1 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F1 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2 · ownership.nature: The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error. Read SEC document
March 03, 2020 Filed Mar 13, 2020 21:20 UTC Amendment	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	2,800	$18.00	$50,400.00	Disclosure SEC source: 0001209191-20-018974 · doc4a.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Read SEC document
March 03, 2020 Filed Mar 13, 2020 21:20 UTC Amendment	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	550,000	$18.00	$9,900,000.00	Disclosure SEC source: 0001209191-20-018974 · doc4a.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By AI Passage LLC Disclosed balance after: 2,616,630 F2 · ownership.nature: The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error. Read SEC document
March 03, 2020 Filed Mar 13, 2020 21:20 UTC Amendment	Passage BIO, Inc. PASG · Entity 7829	ConversionCommon Stock	2,066,630	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018974 · doc4a.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By AI Passage LLC Disclosed balance after: 2,066,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2 · ownership.nature: The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error. Read SEC document
February 27, 2020 Filed Mar 2, 2020 22:58 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (Right to Buy) · Derivative	33,836	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-20-014700 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,836 Underlying: Common Stock · 33,836 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
November 12, 2019 Filed Nov 14, 2019 21:23 UTC	ARVINAS, INC. ARVN · Entity 5355	PurchaseCommon Stock	680,000	$22.00	$14,960,000.00	Disclosure SEC source: 0000899243-19-027280 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,000 F1 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
June 14, 2019 Filed Jun 18, 2019 20:27 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	7,881	$1.67 Strike: $2.43	$13,125.02	Disclosure SEC source: 0001209191-19-037693 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,881 Underlying: Common Stock · 7,881 shares Expires 2029-06-14 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
May 23, 2019 Filed May 28, 2019 21:11 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	12,923	$0.00 Strike: $22.06	$0.00	Disclosure SEC source: 0000899243-19-014879 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,923 Underlying: Common Stock · 12,923 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option award was granted on May 23, 2019. The shares underlying the award shall vest in full on May 23, 2020 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:32 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	4,829	$2.72 Strike: $4.40	$13,127.64	Disclosure SEC source: 0001209191-19-023141 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Common Stock · 4,829 shares Expires 2029-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
March 29, 2019 Filed Apr 2, 2019 16:24 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	4,123	$2.43 Strike: $4.05	$9,998.28	Disclosure SEC source: 0001104659-19-019381 · a4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,123 Underlying: Common Stock · 4,123 shares Expires 2029-03-28 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
March 15, 2019 Filed Mar 18, 2019 21:52 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011935 · form4.xml · derivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F5 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F6 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
March 15, 2019 Filed Mar 18, 2019 21:52 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011935 · form4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:57 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	4,860	$2.70 Strike: $4.47	$13,122.00	Disclosure SEC source: 0001209191-19-002049 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,860 Underlying: Common Stock · 4,860 shares Expires 2029-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	ConversionSeries C Preferred Stock · Derivative	568,252	$0.00	$0.00	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · derivative · entry 6 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 174,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "NLV-III Manager" and collectively, the " NLV-III Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	ConversionSeries B Preferred Stock · Derivative	3,601,657	$0.00	$0.00	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · derivative · entry 5 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,108,202 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "NLV-III Manager" and collectively, the " NLV-III Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	PurchaseCommon Stock	375,000	$16.00	$6,000,000.00	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · nonDerivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,000 F4 · ownership.nature: These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. ("BPO-II"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt, Vijay K. Lathi and Isaac J. Manke are the managers of BPO Management-II (each, a "BPO-II Manager" and collectively, the "BPO-II Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F5 · ownership.nature: (Continued from Footnote 4) The Reporting Person and each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,908,048 F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "NLV-III Manager" and collectively, the " NLV-III Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	ConversionCommon Stock	174,846	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,283,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "NLV-III Manager" and collectively, the " NLV-III Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:22 UTC	ARVINAS, INC. ARVN · Entity 5355	ConversionCommon Stock	1,108,202	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-026073 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,108,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "NLV-III Manager" and collectively, the " NLV-III Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:19 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	2,111	$6.22 Strike: $10.37	$13,130.42	Disclosure SEC source: 0001209191-18-053976 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,111 Underlying: Common Stock · 2,111 shares Expires 2028-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
August 14, 2018 Filed Aug 15, 2018 12:05 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-18-025376 · form4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
July 26, 2018 Filed Sep 26, 2018 22:47 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	1,504	$8.72 Strike: $14.57	$13,114.88	Disclosure SEC source: 0001209191-18-052365 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Underlying: Common Stock · 1,504 shares Expires 2028-07-26 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries B Convertible Preferred Stock · Derivative	6,712,986	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · derivative · entry 10 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 243,345 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F4 · ownership.nature: These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities. F5 · ownership.nature: Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries B Convertible Preferred Stock · Derivative	15,233,315	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · derivative · entry 9 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 552,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-2 Convertible Preferred Stock · Derivative	33,022,786	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · derivative · entry 8 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,197,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-1 Convertible Preferred Stock · Derivative	28,895,188	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · derivative · entry 7 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,047,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	125,000	$16.00	$2,000,000.00	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 6 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 368,345 F6 · shares: On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering. F4 · ownership.nature: These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities. F5 · ownership.nature: Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	125,000	$16.00	$2,000,000.00	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 5 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,734 F6 · shares: On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	243,345	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 243,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F4 · ownership.nature: These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities. F5 · ownership.nature: Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	552,208	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,796,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	1,197,076	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,244,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:53 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	1,047,450	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042308 · a4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,047,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities. F3 · ownership.nature: The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 19, 2018 Filed Jun 20, 2018 20:54 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (Right To Purchase) · Derivative	20,000	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0001127602-18-021621 · form4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document
May 30, 2018 Filed May 31, 2018 16:54 UTC	Iterum Therapeutics plc ITRM · Entity 72802	ConversionSeries B-2 Preferred Shares · Derivative	148,603	$0.00	$0.00	Disclosure SEC source: 0001209191-18-034404 · doc4.xml · derivative · entry 8 Lathi Vijay K · CIK 0001340806 · 10% owner Ratcliffe Liam · CIK 0001547100 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By New Leaf Ventures III, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 148,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F4 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.